8-K: Century Therapeutics Faces Nasdaq Listing Deficiency Due to Low Share Price

Century Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• Century Therapeutics, Inc. received a notification from Nasdaq on February 26, 2025, stating that its common stock has been trading below the required $1.00 per share for 31 consecutive business days.
• This violates Nasdaq Listing Rule 5450(a)(1).
• The company has until August 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for at least 10 consecutive business days.
• If compliance isn't achieved, Century Therapeutics may transfer to the Nasdaq Capital Market, provided it meets other listing requirements.
• Following a transfer to the Nasdaq Capital Market, the Company would be afforded the remainder of the applicable compliance period set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii) which provides an additional 180 days compliance period, unless it does not appear to Nasdaq that it is possible for the Company to cure the deficiency.
• The company intends to monitor its stock price and consider plans to regain compliance, but there's no guarantee it will succeed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the Nasdaq notification and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern.

Positives

• The company has a 180-day period to regain compliance with Nasdaq's listing requirements.
• There is a possibility of transferring to the Nasdaq Capital Market if initial compliance efforts fail, providing an additional compliance period.

Negatives

• Century Therapeutics' stock price has been below $1.00 for 31 consecutive business days, triggering a Nasdaq deficiency notice.
• There is no guarantee that the company will be able to regain compliance with Nasdaq listing rules.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5450(a)(1) could result in delisting from The Nasdaq Global Select Market.
• The company's stock price may be negatively impacted by the Nasdaq notification.
• The company's ability to raise capital may be hindered if it is not in compliance with Nasdaq listing requirements.

Future Outlook

The company intends to monitor its stock price and consider plans for regaining compliance with Nasdaq Listing Rule 5450(a)(1), but there is no assurance that it will be able to do so.

Industry Context

Many biotech companies, especially those in the early stages of development, can face share price volatility and potential listing compliance issues if they don't meet certain financial milestones or experience setbacks in their clinical programs.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is unable to regain compliance with Nasdaq listing requirements.
• Employees may be concerned about the company's future prospects if it faces potential delisting.

Next Steps

• Century Therapeutics will monitor the closing bid price of its common stock.
• Century Therapeutics will consider plans for regaining compliance with Rule 5450(a)(1).

Key Dates